4.80
4.00%
-0.20
2seventy bio Inc 주식(TSVT)의 최신 뉴스
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
2seventy bio executive sells shares worth $73 - Investing.com ZA - Investing.com South Africa
Investing.com South Africa
2seventy bio executive sells shares worth $73 By Investing.com - Investing.com
Investing.com
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks Investment Research
Biopharma Layoff Tracker 2024: Bolt, Tenaya, BioMarin and More Cut Staff - BioSpace
BioSpace
Q2 2024 EPS Estimates for 2seventy bio, Inc. Increased by Wedbush (NASDAQ:TSVT) - MarketBeat
MarketBeat
2seventy bio (NASDAQ:TSVT) Price Target Cut to $11.00 - Defense World
Defense World
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term - Simply Wall St
Simply Wall St
Earnings call: 2seventy bio eyes growth with focus on Abecma in Q1 2024 - Investing.com South Africa
Investing.com South Africa
Canaccord Genuity Group Cuts 2seventy bio (NASDAQ:TSVT) Price Target to $11.00 - MarketBeat
MarketBeat
Earnings call: 2seventy bio eyes growth with focus on Abecma in Q1 2024 - Investing.com Canada
Investing.com Canada
2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research
Zacks Investment Research
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress - 08.05.2024 - wallstreet:online
wallstreet:online
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress - Business Wire
Business Wire
2Seventy Bio earnings missed by $0.26, revenue fell short of estimates - Investing.com South Africa
Investing.com South Africa
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
2seventy bio (TSVT) to Release Earnings on Wednesday - MarketBeat
MarketBeat
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 - Business Wire
Business Wire
For 2seventy bio Insiders, Selling US$769k Of Shares Was A Smart Move - Simply Wall St
Simply Wall St
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks Investment Research
2seventy bio, Inc. (NASDAQ:TSVT) Receives $13.17 Consensus Price Target from Analysts - MarketBeat
MarketBeat
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
Nasdaq
2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by SG Americas Securities LLC - Defense World
Defense World
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
Zacks Investment Research
2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Up 29.7% in March - Defense World
Defense World
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Zacks Investment Research
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros ... - Yahoo Finance
Yahoo Finance
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
Zacks Investment Research
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Zacks Investment Research
Citi raises 2Seventy Bio stock target on FDA approval - Investing.com
Investing.com
Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma - Seeking Alpha
Seeking Alpha
2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround (NASDAQ:TSVT) - Seeking Alpha
Seeking Alpha
2seventy bio Finalizes Asset Sale and Executive Transition - TipRanks.com - TipRanks
TipRanks
2seventy bio focuses solely on Abecma post Regeneron deal - Investing.com
Investing.com
Casdin Capital buys $3.9m in 2seventy bio shares, sells swaps - Investing.com
Investing.com
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
Zacks Investment Research
Pi Health raises $30M; Gamida CSO hired at GRObio; 2seventy bio's drug label expansion - The Business Journals
The Business Journals
2seventy bio Appoints Eli Casdin and Charles Newton to Board of Directors - citybiz
citybiz
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
Zacks Investment Research
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech (NASDAQ:LEGN), Johnson & Johnson (NY - Benzinga
Benzinga
자본화:
|
볼륨(24시간):